Export 25 results:
Author Title [ Type(Desc)] Year
Filters: Author is Matthews, Abigail G  [Clear All Filters]
Journal Article
B. K. Mahmoodi, Nijsten, M., Wijsman, J., Matthews, A. G., and van der Laan, L., ABO-blood groups and risk of abdominal aortic aneurysm and peripheral obstructive artery disease: two sides of the same coin., Thromb Res, vol. 129, no. 1, pp. 89-90, 2012.
E. A. McClure, Sonne, S. C., Winhusen, T., Carroll, K. M., Ghitza, U. E., McRae-Clark, A. L., Matthews, A. G., Sharma, G., Van Veldhuisen, P., Vandrey, R. G., Levin, F. R., Weiss, R. D., Lindblad, R., Allen, C., Mooney, L. J., Haynes, L., Brigham, G. S., Sparenborg, S., Hasson, A. L., and Gray, K. M., Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network., Contemp Clin Trials, vol. 39, no. 2, pp. 211-23, 2014.
J. F. Bobb, Qiu, H., Matthews, A. G., McCormack, J., and Bradley, K. A., Addressing identification bias in the design and analysis of cluster-randomized pragmatic trials: a case study., Trials, vol. 21, no. 1, p. 289, 2020.
W. Ling, Hillhouse, M. P., Saxon, A. J., Mooney, L. J., Thomas, C. M., Ang, A., Matthews, A. G., Hasson, A., Annon, J., Sparenborg, S., Liu, D. S., McCormack, J., Church, S., Swafford, W., Drexler, K., Schuman, C., Ross, S., Wiest, K., P Korthuis, T., Lawson, W., Brigham, G. S., Knox, P. C., Dawes, M., and Rotrosen, J., Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study., Addiction, vol. 111, no. 8, pp. 1416-27, 2016.
L. - T. Wu, John, W. S., Ghitza, U. E., Wahle, A., Matthews, A. G., Lewis, M., Hart, B., Hubbard, Z., Bowlby, L. A., Greenblatt, L. H., and Mannelli, P., Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network., Addiction, 2021.
K. - C. Chang, Der Wang, J. -, Saxon, A., Matthews, A. G., Woody, G., and Hser, Y. - I., Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan., Int J Drug Policy, vol. 43, pp. 1-6, 2017.
J. D. Lee, Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, J., K Peavy, M., Ross, S., Salazar, D., Schkolnik, P., Shmueli-Blumberg, D., Stablein, D., Subramaniam, G., and Rotrosen, J., Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial., Lancet, vol. 391, no. 10118, pp. 309-318, 2018.
E. A. McClure, King, J. S., Wahle, A., Matthews, A. G., Sonne, S. C., Lofwall, M. R., McRae-Clark, A. L., Ghitza, U. E., Martinez, M., Cloud, K., Virk, H. S., and Gray, K. M., Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States., Drug Alcohol Depend, vol. 176, pp. 14-20, 2017.
J. Lorenzo Bermejo, Perez, A. Garcia, Brandt, A., Hemminki, K., and Matthews, A. G., Comparison of six statistics of genetic association regarding their ability to discriminate between causal variants and genetically linked markers., Hum Hered, vol. 72, no. 2, pp. 142-52, 2011.
M. Lehmann, Veitz-Keenan, A., Matthews, A. G., Vena, D., Grill, A., Craig, R. G., Curro, F. A., and Thompson, V. P., Dentin caries activity in early occlusal lesions selected to receive operative treatment: findings from the Practitioners Engaged in Applied Research and Learning (PEARL) Network., J Am Dent Assoc, vol. 143, no. 4, pp. 377-85, 2012.
D. M. Boudreau, Lapham, G., Johnson, E. A., Bobb, J. F., Matthews, A. G., McCormack, J., Liu, D., Campbell, C. I., Rossom, R. C., Binswanger, I. A., Yarborough, B. Jo, Arnsten, J. H., Cunningham, C. O., Glass, J. E., Murphy, M. T., Zare, M., Hechter, R. C., Ahmedani, B., Braciszewski, J. M., Horigian, V. E., Szapocznik, J., Samet, J. H., Saxon, A. J., Schwartz, R. P., and Bradley, K. A., Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems., J Subst Abuse Treat, vol. 112S, pp. 41-48, 2020.
B. Strober, Veitz-Keenan, A., Barna, J. Ann, Matthews, A. G., Vena, D., Craig, R. G., Curro, F. A., and Thompson, V. P., Effectiveness of a resin-modified glass ionomer liner in reducing hypersensitivity in posterior restorations: a study from the practitioners engaged in applied research and learning network., J Am Dent Assoc, vol. 144, no. 8, pp. 886-97, 2013.
A. N. C. Campbell, Nunes, E. V., Matthews, A. G., Stitzer, M., Miele, G. M., Polsky, D., Turrigiano, E., Walters, S., McClure, E. A., Kyle, T. L., Wahle, A., Van Veldhuisen, P., Goldman, B., Babcock, D., Stabile, P. Quinn, Winhusen, T., and Ghitza, U. E., Internet-delivered treatment for substance abuse: a multisite randomized controlled trial., Am J Psychiatry, vol. 171, no. 6, pp. 683-90, 2014.
M. T. Botello-Harbaum, Matthews, A. G., Collie, D., Vena, D. A., Craig, R. G., Curro, F. A., Thompson, V. P., and Broder, H. L., Level of oral health impacts among patients participating in PEARL: a dental practice-based research network., Community Dent Oral Epidemiol, vol. 40, no. 4, pp. 332-42, 2012.
Y. - I. Hser, Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., Hatch-Maillette, M., Jelstrom, E., Wiest, K., McLaughlin, P., and Ling, W., Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial., Addiction, vol. 111, no. 4, pp. 695-705, 2016.
T. Winhusen, Lofwall, M., Jones, H. E., Wilder, C., Lindblad, R., Schiff, D. M., Wexelblatt, S., Merhar, S., Murphy, S. M., Greenfield, S. F., Terplan, M., Wachman, E. M., Kropp, F., Theobald, J., Lewis, M., Matthews, A. G., Guille, C., Silverstein, M., and Rosa, C., Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations., Contemp Clin Trials, vol. 93, p. 106014, 2020.
L. A. Devlin, Young, L. W., Kraft, W. K., Wachman, E. M., Czynski, A., Merhar, S. L., Winhusen, T., Jones, H. E., Poindexter, B. B., Wakschlag, L. S., Salisbury, A. L., Matthews, A. G., and Davis, J. M., Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants., J Perinatol, 2021.
Y. Jo Wong, Keenan, J., Hudson, K., Bryan, H., Naftolin, F., Thompson, V. P., Craig, R. G., Vena, D., Collie, D., Wu, H., Matthews, A. G., Grill, A. C., and Curro, F. A., Opioid, NSAID, and OTC Analgesic Medications for Dental Procedures: PEARL Network Findings., Compend Contin Educ Dent, vol. 37, no. 10, pp. 710-718, 2016.
S. D. Bernstein, Horowitz, A. J., Man, M., Wu, H., Foran, D., Vena, D. A., Collie, D., Matthews, A. G., Curro, F. A., Thompson, V. P., and Craig, R. G., Outcomes of endodontic therapy in general practice: a study by the Practitioners Engaged in Applied Research and Learning Network., J Am Dent Assoc, vol. 143, no. 5, pp. 478-87, 2012.
J. A. Martin, Grill, A. C., Matthews, A. G., Vena, D., Thompson, V. P., Craig, R. G., and Curro, F. A., Periodontal diagnosis affected by variation in terminology., J Periodontol, vol. 84, no. 5, pp. 606-13, 2013.
C. I. Campbell, Saxon, A. J., Boudreau, D. M., Wartko, P. D., Bobb, J. F., Lee, A. K., Matthews, A. G., McCormack, J., Liu, D. S., Addis, M., Altschuler, A., Samet, J. H., LaBelle, C. T., Arnsten, J., Caldeiro, R. M., Borst, D. T., Stotts, A. L., Braciszewski, J. M., Szapocznik, J., Bart, G., Schwartz, R. P., McNeely, J., Liebschutz, J. M., Tsui, J. I., Merrill, J. O., Glass, J. E., Lapham, G. T., Murphy, S. M., Weinstein, Z. M., Yarborough, B. Jo H., and Bradley, K. A., PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment., Addict Sci Clin Pract, vol. 16, no. 1, p. 9, 2021.
K. M. Gray, Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., Hasson, A., Walsh, S. L., Lofwall, M. R., Babalonis, S., Lindblad, R. W., Sparenborg, S., Wahle, A., King, J. S., Baker, N. L., Tomko, R. L., Haynes, L. F., Vandrey, R. G., and Levin, F. R., A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults., Drug Alcohol Depend, vol. 177, pp. 249-257, 2017.
P. Blanchard, Wong, Y., Matthews, A. G., Vena, D., Craig, R. G., Curro, F. A., and Thompson, V. P., Restoration variables and postoperative hypersensitivity in Class I restorations: PEARL Network findings. Part 2., Compend Contin Educ Dent, vol. 34, no. 4, pp. e62-8, 2013.
J. McNeely, Wright, S., Matthews, A. G., Rotrosen, J., Shelley, D., Buchholz, M. P., and Curro, F. A., Substance-use screening and interventions in dental practices: survey of practice-based research network dentists regarding current practices, policies and barriers., J Am Dent Assoc, vol. 144, no. 6, pp. 627-38, 2013.
A. Veitz-Keenan, Barna, J. Ann, Strober, B., Matthews, A. G., Collie, D., Vena, D., Curro, F. A., and Thompson, V. P., Treatments for hypersensitive noncarious cervical lesions: a Practitioners Engaged in Applied Research and Learning (PEARL) Network randomized clinical effectiveness study., J Am Dent Assoc, vol. 144, no. 5, pp. 495-506, 2013.